Back to search

Article

The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor Phenotypes

2019-10-31

Abstract excerpt

In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the prote...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1fee0d4f-0c58-538f-8e11-08cf7719d229
DOI
10.20944/preprints201910.0373.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor PhenotypesDOI 10.20944/preprints201910.0373.v1
Histopathology-assisted proteogenomics provides foundations for stratification of melanoma metastasesSemantic proximity
Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.Semantic proximity
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.Semantic proximity
Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance.Semantic proximity
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Semantic proximity
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.Semantic proximity
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaSemantic proximity
Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-OutSemantic proximity
A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.Semantic proximity
Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status.Semantic proximity
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.Semantic proximity
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.Semantic proximity
Select a neighboring publication to make it the new centre.